<DOC>
	<DOC>NCT00877032</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of RN6G in patients with dry, age-related macular degeneration.</brief_summary>
	<brief_title>Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Retinal Degeneration</mesh_term>
	<criteria>Be of nonchildbearing potential. Diagnosis of dry AMD as defined by the AgeRelated Eye Disease Study (AREDS, 2005), including uni or multifocal GA, without foveal involvement. BCVA of 20/320 or better in the worst eye. Diagnosis of exudative (wet) AMD, with subretinal or choroidal neovascular lesions. Diagnosis or history of Alzheimer's disease, dementia or neurodegenerative disorders. Diagnosis or recent history of clinically significant cerebrovascular disease. Uncontrolled hypertension. Uncontrolled Type 1 or Type 2 diabetes mellitus.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Dry Age Related Macular Degeneration</keyword>
	<keyword>RN6G</keyword>
</DOC>